---
title: "Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Definition and etiology"
description: "Formulary evidence on Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Definition and etiology. Topics: Steatotic liver disease nomenclature: MASLD replaces NAFLD and MASH replaces NASH; MASLD as a disease spectrum from steatosis to MASH, fibrosis, cirrhosis, and hepatocellular carcinoma; Fibrosis staging retained under the new nomenclature, including MASH with stage 3 fibrosis; At-risk NASH defined as biopsy-proven NASH with stage 2 or higher fibrosis; 5 further topics. 9 evidence topics quoted from 6 sources."
canonical: "https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description/definition-and-etiology"
published: "2026-11-18T22:34:49-05:00"
modified: "2026-11-18T22:34:49-05:00"
---

# Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Definition and etiology

<a id="heading-2.2.1.1"></a>

## 2.2.1.1 Definition and Etiology

<a id="topic-2.2.1.1-1"></a>

### Steatotic liver disease nomenclature: MASLD replaces NAFLD and MASH replaces NASH

> “Steatotic liver disease was chosen as an overarching term to encompass the various aetiologies of steatosis.”
> “The name chosen to replace NAFLD was metabolic dysfunction–associated steatotic liver disease.”
> “There was consensus to change the definition to include the presence of at least 1 of 5 cardiometabolic risk factors.”
> “In total, 75% of respondents of the external expert committee chose MASLD as the replacement term for NAFLD and 88% metabolic dysfunction–associated steatohepatitis (MASH) as the replacement term for NASH.”
> “Persons with MASLD and steatohepatitis will be designated as metabolic dysfunction associated steatohepatitis (MASH).”

Source: [Rinella et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10653297/)

<a id="topic-2.2.1.1-2"></a>

### MASLD as a disease spectrum from steatosis to MASH, fibrosis, cirrhosis, and hepatocellular carcinoma

> “Metabolic dysfunction-associated steatotic liver disease (MASLD) is the umbrella term that comprises metabolic dysfunction-associated steatotic liver, or isolated hepatic steatosis, through to metabolic dysfunction-associated steatohepatitis, the progressive necroinflammatory disease form that can progress to fibrosis, cirrhosis and hepatocellular carcinoma.”
> “MASLD is closely associated with insulin resistance, obesity, gut microbial dysbiosis and genetic risk factors.”

Source: [Huang et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40050362/)

<a id="topic-2.2.1.1-3"></a>

### Fibrosis staging retained under the new nomenclature, including MASH with stage 3 fibrosis

> “The new names also allow for further characterisation of fibrotic severity, for example, MASH with stage 3 fibrosis.”
> “Disease staging and severity are not altered by this process although it is anticipated that, in the near to medium term, disease staging will be achieved using noninvasive tests, which can be incorporated into further clarifications of disease stage.”

Source: [Rinella et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10653297/)

<a id="topic-2.2.1.1-4"></a>

### At-risk NASH defined as biopsy-proven NASH with stage 2 or higher fibrosis

> “Identifying patients with “at-risk” NASH (biopsy-proven NASH with stage 2 or higher fibrosis) is a more recent area of interest.”

Source: [Rinella et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10735173/)

<a id="topic-2.2.1.1-5"></a>

### Continuity of NAFLD and NASH evidence with MASLD and MASH: European registry and US NHANES overlap

> “an analysis of the LITMUS consortium European was performed, which demonstrated that 98% of the existing registry cohort of patients with NAFLD would fulfill the new criteria for MASLD”
> “maintenance of the term, and clinical definition, of steatohepatitis ensures retention and validity of prior data from clinical trials and biomarker discovery studies of patients with NASH to be generalisable to individuals classified as MASLD or MASH under the new nomenclature, without impeding the efficiency of research.”

Source: [Rinella et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10653297/)

> “There was 99% overlap in cases of NAFLD and MASLD.”
> “Among those with NAFLD or MASLD, 99.0% (95% CI 97.6%–99.6%) met the criteria for both NAFLD and MASLD.”

Source: [Lee et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11232657/)

<a id="topic-2.2.1.1-6"></a>

### Cardiometabolic risk factors in the definition of MASLD: adult criteria

> “Hepatic steatosis is the hallmark of MASLD, defined as the presence of hepatic steatosis in conjunction with at least one cardiometabolic risk factor (Table 3) and no other discernible cause.”

Source: [European Association for the Study of the Liver (2024)](https://www.journal-of-hepatology.eu/article/S0168-8278%2824%2900329-5/fulltext)

| Metabolic risk factor | Adult criteria |
| --- | --- |
| Overweight or obesity: body mass index | “≥25 kg/m2 (≥23 kg/m2 in people of Asian ethnicity)” |
| Overweight or obesity: waist circumference (Europeans) | “≥94 cm in men and ≥80 cm in women (Europeans)” |
| Overweight or obesity: waist circumference (South Asians and Chinese) | “≥90 cm in men and ≥80 cm in women (South Asians and Chinese)” |
| Dysglycaemia: prediabetes | “Prediabetes: HbA1c 39-47 mmol/mol (5.7-6.4%) or fasting plasma glucose 5.6-6.9 mmol/L (100-125 mg/dl)” |
| Type 2 diabetes | “Type 2 diabetes: HbA1c ≥48 mmol/mol (≥6.5%) or fasting plasma glucose ≥7.0 mmol/L (≥126 mg/dl)”; “Treatment for type 2 diabetes” |
| Plasma triglycerides | “≥1.7 mmol/L (≥150 mg/dl) or lipid-lowering treatment” |
| HDL-cholesterol | “≤1.0 mmol/L (≤39 mg/dl) in men and ≤1.3 mmol/L (≤50 mg/dl) in women or lipid-lowering treatment” |
| Blood pressure | “≥130/85 mmHg or treatment for hypertension” |

Source: [European Association for the Study of the Liver (2024)](https://www.journal-of-hepatology.eu/article/S0168-8278%2824%2900329-5/fulltext)

<a id="topic-2.2.1.1-7"></a>

### Alcohol intake thresholds separating MASLD, MetALD, and alcohol-related liver disease

> “MASLD and ALD (alcohol intake >50 g/day for females and >60 g/day for males) comprise the most common causes of SLD.”
> “A new category, requiring further characterisation, termed MetALD, describes those with MASLD who consume greater amounts of alcohol (20-50 g/day for females and 30-60 g/day for males, respectively), but do not meet the criteria for ALD.”
> “MASLD, ALD and MetALD are the most common causes of SLD, but other causes such as drug-induced liver disease and monogenic SLD should be considered, depending on the context (LoE 3, strong recommendation, strong consensus).”

Source: [European Association for the Study of the Liver (2024)](https://www.journal-of-hepatology.eu/article/S0168-8278%2824%2900329-5/fulltext)

<a id="topic-2.2.1.1-8"></a>

### Etiology: type 2 diabetes, obesity, age, and menopausal status as risk factors for progressive fibrosis

> “Type 2 diabetes and obesity (particularly abdominal obesity) are the metabolic diseases with the strongest impact on the natural history of MASLD, including progression to MASLD/MASH-related advanced fibrosis, cirrhosis and hepatocellular carcinoma (LoE 2, strong consensus).”
> “Males aged >50 years, postmenopausal women, and individuals with multiple cardiometabolic risk factors are at increased risk of progressive fibrosis and the development of cirrhosis and its complications (LoE 2, strong consensus).”

Source: [European Association for the Study of the Liver (2024)](https://www.journal-of-hepatology.eu/article/S0168-8278%2824%2900329-5/fulltext)

> “T2DM is the most impactful risk factor for the development of NAFLD, fibrosis progression, and HCC”
> “NAFLD is closely linked to and often precedes the development of metabolic abnormalities (insulin resistance, dyslipidemia, central obesity, and hypertension).”

Source: [Rinella et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10735173/)

<a id="topic-2.2.1.1-9"></a>

### Etiology: inherited risk, PNPLA3 and TM6SF2 variants, and heritability

> “Inherited factors play a major role in the development and progression of MASLD, synergising with the metabolic causes of the disease.”
> “Overall evidence suggests that the PNPLA3 p.I148M and TM6SF2 p.E167K variants are major risk factors for progressive MASLD”

Source: [European Association for the Study of the Liver (2024)](https://www.journal-of-hepatology.eu/article/S0168-8278%2824%2900329-5/fulltext)

> “NAFLD and NASH have a heritable component that is estimated to be between 35%–61%”
> “The PNPLA3 gene is a major driver of NAFLD, NASH, cirrhosis, and HCC risk in individuals who have metabolic risk factors such as obesity, diabetes, and metabolic syndrome.”

Source: [Loomba et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12168897/)

## Related pages
- [Lanifibranor (IVA337): Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Terms and abbreviations](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/terms-and-abbreviations.md)
- [Lanifibranor (IVA337): Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/executive-summary.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Product information and disease description](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Clinical evidence](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/clinical-evidence.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Economic information and modeling report](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/economics) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/economics.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: References](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/references) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/references.md)
